Full Press Release Details
Tiziana Life Sciences Ltd
("Tiziana" or "the Company")
Interim Results for the Six Months Ended 30
Advancing pipeline of next generation therapeutics
and diagnostics for oncology and immune diseases of high unmet need
London, 27 December 2022 - Tiziana Life
Sciences Ltd ("Tiziana", NASDAQ: TLSA), a biotechnology company focused on innovative therapeutics for oncology, inflammation,
and infectious diseases today announces its interim results for the six months ended 30 June 2022.
Highlights during the period:
CLINICAL and NON-CLINICAL PROGRAMMES
TZLS-501, formerly NI-1201
Intellectual Property
and interim arrangements
Highlights post period end:
The Company continues to carefully manage its
working capital position and continues the process, as referred to below, to evaluate opportunities to raise further funds through the
issue of additional equity capital.
About Tiziana Life Sciences
Tiziana Life Sciences
is a clinical-stage biopharmaceutical company developing breakthrough immunomodulation therapies via novel routes of drug delivery. Tiziana's
innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety
and tolerability compared to intravenous (IV) delivery. Tiziana's two lead candidates, intranasal foralumab, the only fully human
anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients
in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending
and is expected to allow for broad pipeline applications.